ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Allergan Pharmaceuticals is paying Exicure $25 million to develop new hair-loss treatments using Exicure’s spherical nucleic acid (SNA) technology. SNAs are nanoparticles with an array of oligonucleotides attached to the surface that can be absorbed through the skin. The companies are collaborating on two programs, and Exicure could earn up to $362.5 million in developmental, regulatory, and commercial milestones for each program.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X